Comparative Analysis of Migraine Recurrence and Quality of Life Outcomes in Patients Undergoing Modern Medicine Therapies: A Systematic Review

Background : Migraine is a chronic neurological disorder affecting millions worldwide, often leading to a reduced quality of life and economic burden. While modern pharmacological treatments are widely used, migraine recurrence remains a concern. This study systematically reviews literature on migraine recurrence and quality of life outcomes in patients treated with allopathic therapies. Objective : To assess the recurrence rates, effectiveness, and impact on quality of life in migraine patients undergoing modern pharmacological treatments. Methods : A systematic review was conducted across PubMed, MEDLINE, EBSCO, and Cochrane Library databases, analyzing peer-reviewed studies from the last 15 years on allopathic migraine management. Extracted data included study design, treatment types, recurrence rates, and patient satisfaction. Statistical analyses included descriptive statistics, chi-square tests, ANOVA, and multivariate logistic regression models . Risk ratios (RR) and odds ratios (OR) were calculated for recurrence rates. Sensitivity analyses were performed for missing data (< 5%). Statistical software SPSS 27.0 and R 4.1.2 were used for data analysis. Results : Among 500 migraine patients , 200 (40%) experienced recurrence within six months . Mean reduction in headache days was 7.2 days (SD = 3.1) , and median headache intensity was 5.5 (IQR: 3.2–7.1) . Recurrence rates: Triptans : 45.2% (95% CI: 39.1%-51.3%) CGRP inhibitors : 22.3% (95% CI: 18.4%-26.2%) Risk reduction with CGRP inhibitors vs. Triptans : RR = 0.49 (95% CI: 0.38–0.64, p < 0.001) . Medication adherence was inversely correlated with recurrence (Pearson’s r = -0.52, p = 0.002). Conclusion : Modern pharmacological treatments significantly reduce migraine frequency and improve quality of life, yet recurrence remains a concern. CGRP inhibitors offer superior efficacy , but adherence and comorbidities influence outcomes. Future studies should explore integrative treatment approaches combining allopathic and traditional therapies for long-term migraine management.